Vivos (RDGL) Capital Expenditures (2010 - 2017)
Vivos' (RDGL) quarterly Capital Expenditures came in at $2800.0 in Q1 2017, down 71.29% quarter-over-quarter from $9754.0 in Q1 2013.
Powered by 
Analysis
Vivos (RDGL) Capital Expenditures (2010 - 2017) Analysis & Trends
Vivos has disclosed Capital Expenditures across 4 years of filings, most recently posting $2800.0 for Q1 2017.
- In Q1 2017, Capital Expenditures changed N/A year-over-year to $2800.0; the TTM figure through Mar 2017 stood at -$72124.0 (changed N/A YoY), while the FY2025 annual figure was $103185.0, changed N/A from the prior year.
- Capital Expenditures came in at $2800.0 for Q1 2017 at Vivos, down from $9754.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $9754.0 in Q1 2013 to a low of $2800.0 in Q1 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | 497.00 Mn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | 112.60 Mn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | 503.00 Mn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | 202.00 Mn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | 195.00 Mn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | 66.90 Mn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | -96.00 Mn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | 84.70 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | 87.50 Mn |
| 10 | Vivos | 23.21 Mn | 23.21 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2017 | 2,800.00 |
| Mar 31, 2013 | 9,754.00 |
| Dec 31, 2012 | -84,678.00 |
| Dec 31, 2010 | 28,690.00 |